Comparative Pharmacology
Head-to-head clinical analysis: DANOCRINE versus DELATESTRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANOCRINE versus DELATESTRYL.
DANOCRINE vs DELATESTRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Danazol is a synthetic androgen derived from ethisterone. It suppresses the pituitary-ovarian axis by inhibiting gonadotropin (LH and FSH) release, leading to anovulation and amenorrhea. It also binds to androgen, progesterone, and glucocorticoid receptors, exerting weak androgenic, antiestrogenic, and antigonadotropic effects. Additionally, it may directly inhibit ovarian steroidogenesis and increase clearance of endogenous sex hormones.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
100-200 mg orally twice daily for endometriosis; 200-400 mg twice daily for fibrocystic breast disease; 200 mg twice daily for hereditary angioedema. Maximum dose: 800 mg/day.
50 to 200 mg intramuscularly every 2 to 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 10–30 hours (mean 15 hours); clinically, steady-state reached after 2–4 days.
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Renal (metabolites, ~50%), biliary/fecal (~30%), unchanged drug minimal.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Category C
Category C
Androgen/Antigonadotropin
Androgen